title: [Efficacy of crizotinib for 28 cases of advanced ALK-positive non-small cell lung cancer].
abstract: OBJECTIVE
  This study aims to evaluate the efficacy and safety of crizotinib for advanced ALK-positive non-small cell lung cancer (NSCLC) patients.
  
  
  METHODS
  Twenty-eight patients with advanced ALK-positive NSCLC were given orally crizotinib 250 mg b. i.d., and were followed up to evaluate the therapeutic efficacy and safety.
  
  
  RESULTS
  Among the 28 patients, the objective response rate (ORR) was 71.4% (20/28) and disease control rate (DCR) was 92.9% (26/28). Three patients achieved complete response. Seventeen patients had partial response. The most common drug-related adverse events were mild flickering vision and gastrointestinal reaction. Eleven patients experienced flickering vision. Nine patients had nausea and vomiting. Eight patients had diarrhea. They were all reversible and of grade I or II. Only one patient had grade III myelosuppression. Among the 28 patients, 16 cases were disease-free and 12 cases had progressive disease, with a progression-free survival of 8.2 months.
  
  
  CONCLUSIONS
  Crizotinib is effective and tolerable in the treatment of advanced ALK-positive NSLCC. However, its long-term treatment efficacy requires to be further studied.
authors.affiliation: Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Wenxian
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Zhengbo
authors.initials: Z
authors.lastname: Song
authors.affiliation: Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Xinmin
authors.initials: X
authors.lastname: Yu
authors.affiliation: Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Guangyuan
authors.initials: G
authors.lastname: Lou
authors.affiliation: Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Cuiping
authors.initials: C
authors.lastname: Gu
authors.affiliation: Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Xun
authors.initials: X
authors.lastname: Shi
authors.affiliation: Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China; Email: zyp@medmail.com.cn.
authors.forename: Yiping
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D000077547:Crizotinib; D003967:Diarrhea / Q000139:chemically induced; D018572:Disease-Free Survival; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D009325:Nausea / Q000139:chemically induced; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D020794:Receptor Protein-Tyrosine Kinases